Guardant Health, Inc.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider trading arrangements
During the fiscal quarter ended September 30, 2025, none of our directors or officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, except as described in the table below:
| Name and Title of Insider · Adoption, Modification or Termination · Applicable Date · Duration of Trading Arrangement · Rule 10b5-1 Trading Arrangement?(Y / N) (1) · Aggregate Number of Securities Subject to the Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Terilyn Juarez Monroe, Chief People Officer | Adoption | 8/2/2025 | 10/31/2025 – 5/3/2026 | Y | Indeterminable | (2) |
| AmirAli Talasaz, Co-Chief Executive Officer and Director(3) | Termination | 8/26/2025 | 5/1/2025 – 4/30/2026 | Y | 540,000 | |
(1)Denotes whether the trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) when adopted.
(2)Ms. Monroe’s 10b5-1 trading plan provides for the sale of (i)30,000 shares of our common stock upon exercise of stock options plus (ii) an indeterminable number of shares of our common stock underlying certain restricted stock unit and performance share unit awards that will vest during the duration of the trading arrangement.
(3)The plan was adopted by a trust as to which Mr. Talasaz has voting and dispositive power over the shares held by the trust.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.